Stockreport

Merck: Aggressive M&A Efforts To Prepare For A Keytruda Patent Cliff [Seeking Alpha]

Merck & Company, Inc. (new)  (MRK) 
Last merck & company, inc. (new) earnings: 4/28 06:45 am Check Earnings Report
US:NYSE Investor Relations: investors.merck.com/home/default.aspx
PDF Merck remains heavily reliant on Keytruda, now over 50% of sales, with patent expiry risks looming in 2028-2029 despite pipeline efforts. Recent M&A, including Cidara [Read more]